Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia

被引：4

作者：

Al-Sawaf, Othman ^{[1
]}

Herling, Carmen Diana ^{[1
]}

Holtick, Udo ^{[1
]}

Scheid, Christoph ^{[1
]}

Cramer, Paula ^{[1
]}

Sasse, Stephanie ^{[1
]}

von Tresckow, Bastian ^{[1
]}

Tuchscherer, Armin ^{[1
]}

Fischer, Kirsten ^{[1
]}

Eichhorst, Barbara ^{[1
]}

Hallek, Michael ^{[1
]}

Frenzel, Lukas P. ^{[1
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany

来源：

HAEMATOLOGICA | 2019年 / 104卷 / 05期

关键词：

HIGH-RISK CLL; IBRUTINIB;

D O I：

10.3324/haematol.2018.212837

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：E224 / E226

页数：3

共 15 条

[1] Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia [J].

Davids, Matthew S. ;

Hallek, Michael ;

Wierda, William ;

Roberts, Andrew W. ;

Stilgenbauer, Stephan ;

Jones, Jeffrey A. ;

Gerecitano, John F. ;

Kim, Su Young ;

Potluri, Jalaja ;

Busman, Todd ;

Best, Andrea ;

Verdugo, Maria E. ;

Cerri, Elisa ;

Desai, Monali ;

Hillmen, Peter ;

Seymour, John F. .

CLINICAL CANCER RESEARCH, 2018, 24 (18) :4371-4379

[2] High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies [J].

Dreger, Peter ;

Ghia, Paolo ;

Schetelig, Johannes ;

van Gelder, Michel ;

Kimby, Eva ;

Michallet, Mauricette ;

Moreno, Carol ;

Robak, Tadeusz ;

Stilgenbauer, Stephan ;

Montserrat, Emili .

BLOOD, 2018, 132 (09) :892-902

[3] Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? [J].

Dreger, Peter ;

Schetelig, Johannes ;

Andersen, Niels ;

Corradini, Paolo ;

van Gelder, Michel ;

Gribben, John ;

Kimby, Eva ;

Michallet, Mauricette ;

Moreno, Carol ;

Stilgenbauer, Stephan ;

Montserrat, Emili .

BLOOD, 2014, 124 (26) :3841-3849

[4] Venetoclax and obinutuzumab in chronic lymphocytic leukemia [J].

Fischer, Kirsten ;

Al-Sawaf, Othman ;

Fink, Anna-Maria ;

Dixon, Mark ;

Bahlo, Jasmin ;

Warburton, Simon ;

Kipps, Thomas J. ;

Weinkove, Robert ;

Robinson, Sue ;

Seiler, Till ;

Opat, Stephen ;

Owen, Carolyn ;

Lopez, Javier ;

Humphrey, Kathryn ;

Humerickhouse, Rod ;

Tausch, Eugen ;

Frenzel, Lukas ;

Eichhorst, Barbara ;

Wendtner, Clemens-M. ;

Stilgenbauer, Stephan ;

Langerak, Anton W. ;

van Dongen, Jacque J. M. ;

Boettcher, Sebastian ;

Ritgen, Matthias ;

Goede, Valentin ;

Mobasher, Mehrdad ;

Hallek, Michael .

BLOOD, 2017, 129 (19) :2702-2705

[5] Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance [J].

Gabriel, Sarah Sharon ;

Bon, Nina ;

Chen, Jin ;

Wekerle, Thomas ;

Bushell, Andrew ;

Fehr, Thomas ;

Cippa, Pietro Ernesto .

FRONTIERS IN IMMUNOLOGY, 2016, 7

[6] How and when I do allogeneic transplant in CLL [J].

Gribben, John G. .

BLOOD, 2018, 132 (01) :31-39

[7] Chronic lymphocytic leukaemia [J].

Hallek, Michael ;

Shanafelt, Tait D. ;

Eichhorst, Barbara .

LANCET, 2018, 391 (10129) :1524-1537

[8] Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial [J].

Kraemer, Isabelle ;

Stilgenbauer, Stephan ;

Dietrich, Sascha ;

Boettcher, Sebastian ;

Zeis, Matthias ;

Stadler, Michael ;

Bittenbring, Jorg ;

Uharek, Lutz ;

Scheid, Christof ;

Hegenbart, Ute ;

Ho, Anthony ;

Hallek, Michael ;

Kneba, Michael ;

Schmitz, Norbert ;

Doehner, Hartmut ;

Dreger, Peter .

BLOOD, 2017, 130 (12) :1477-1480

[9] Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation [J].

Link, C. S. ;

Teipel, R. ;

Heidenreich, F. ;

Ruecker-Braun, E. ;

Schmiedgen, M. ;

Reinhardt, J. ;

Oelschlaegel, U. ;

von Bonin, M. ;

Middeke, J. M. ;

Muetherig, A. ;

Trautmann-Grill, K. ;

Platzbecker, U. ;

Bornhaeuser, M. ;

Schetelig, J. .

BONE MARROW TRANSPLANTATION, 2016, 51 (06) :793-798

[10] Ibrutinib for chronic graft-versus-host disease after failure of prior therapy [J].

Miklos, David ;

Cutler, Corey S. ;

Arora, Mukta ;

Waller, Edmund K. ;

Jagasia, Madan ;

Pusic, Iskra ;

Flowers, Mary E. ;

Logan, Aaron C. ;

Nakamura, Ryotaro ;

Blazar, Bruce R. ;

Li, Yunfeng ;

Chang, Stephen ;

Lal, Indu ;

Dubovsky, Jason ;

James, Danelle F. ;

Styles, Lori ;

Jaglowski, Samantha .

BLOOD, 2017, 130 (21) :2243-2250

← 1 2 →